Nanotechnology Now

Our NanoNews Digest Sponsors



Heifer International

Wikipedia Affiliate Button


android tablet pc

Home > News > Major Commitment to Nanotechnology for Cancer Research

October 13th, 2004

Major Commitment to Nanotechnology for Cancer Research

Abstract:
The National Cancer Institute (NCI) announced today at a media briefing a new $144.3 million, five-year initiative to develop and apply nanotechnology to cancer.

Story:

National Cancer Institute Announces Major Commitment to Nanotechnology for Cancer Research

Bethesda, MD – September 13, 2004

The National Cancer Institute (NCI) announced today at a media briefing a new $144.3 million, five-year initiative to develop and apply nanotechnology to cancer. Nanotechnology, the development and engineering of devices so small that they are measured on a molecular scale, has already demonstrated promising results in cancer research and treatment.

"Nanotechnology has the potential to radically increase our options for prevention, diagnosis, and treatment of cancer," said Andrew von Eschenbach, M.D., director of the National Cancer Institute. "NCI's commitment to this cancer initiative comes at a critical time. Nanotechnology supports and expands the scientific advances in genomics and proteomics and builds on our understanding of the molecular underpinnings of cancer. These are the pillars which will support progress in cancer."

To carry out this initiative, the NCI, part of the National Institutes of Health, is forming the NCI Alliance for Nanotechnology in Cancer, a comprehensive, integrated initiative encompassing researchers, clinicians, and public and private organizations that have joined forces to develop and translate cancer-related nanotechnology research into clinical practice.

"The Alliance lays out a process to safely accelerate the application of nanotechnology to cancer research," said NCI Deputy Director Anna Barker, Ph.D. "Central to this initiative will be multidisciplinary partnerships involving physicists, biologists, clinicians, engineers, and other experts that can translate knowledge on cancer and nanotechnology into clinically useful products."

The new NCI Alliance for Nanotechnology in Cancer is one of the first steps in implementing the Cancer Nanotechnology Plan, which was developed over the past 18 months with the input of a broad cross-section of the cancer research and clinical oncology communities. The NCI Alliance consists of four major program activities:

  • Centers of Cancer Nanotechnology Excellence (CCNEs): The primary goal of the CCNEs is to integrate nanotechnology development into basic and applied cancer research. Each center will be affiliated with a NCI Comprehensive Cancer Center, university, or research center of engineering and physical science. By leveraging existing NCI resources, these centers will bridge gaps in the development pipeline from materials discovery to preclinical testing.
  • Multidisciplinary research teams: Given the multidisciplinary nature of nanotechnology research, investigators with basic science and clinical backgrounds will require training to optimize the development and translation of nanotechnologies toward clinical oncology applications. The NCI will initially use existing career development mechanisms to direct talent to this area, create incentives for cross-disciplinary research, and foster collaboration through training.
  • Nanotechnology platforms for cancer research: Over the next five years, investigator-initiated and directed project research will be supported in six key programmatic areas: molecular imaging and early detection, in vivo imaging, reporters of efficacy (e.g., real-time assessment of treatment), multifunctional therapeutics, prevention and control, and research enablers (opening new pathways for research).
  • Nanotechnology Characterization Laboratory (NCL): The NCL will perform and standardize the pre-clinical characterization of nanomaterials developed by researchers from academia, government, and industry. The NCL will serve as a national resource and knowledge base for cancer researchers, and facilitate the accelerated regulatory review and translation of nanomaterials and devices into the clinical realm.

The NCI recently signed a memorandum of understanding and an interagency agreement with the National Institute of Standards and Technology to partner with the NCI in this characterization and standardization effort. The NCI will also be working to expand collaborations with the U.S. Food and Drug Administration (FDA) to help define the critical pathway for nanotechnologies to reach the clinic.

Among the key components of the Cancer Nanotechnology Plan are milestones to measure success over two time periods. Within the first three years, the plan calls for acceleration of projects that hold promise for near-term clinical application. After three years, the Alliance will focus on developing solutions to address more difficult technological and biological problems that have the potential to impact detection and treatment.

"We are already seeing how nanotechnology is transforming our ability to translate research advances into clinical advances," said Samuel Wickline, M.D., Professor of Medicine, Physics and Biomedical Engineering at Washington University, St. Louis, Mo., and NCI grantee for nanotechnology research. "The possibilities are enormous for finding very small cancers far earlier than ever before and treating them with powerful drugs at the tumor site alone, while at the same time reducing any harmful side effects. This initiative will allow us to explore using this technology to its full potential."

Recent advances in cancer treatment involving nanotechnology include:

  • Liposomes, the "first generation" of nanoscale drug delivery devices, were developed to deliver anticancer therapeutics directly at tumors. Specifically, liposomal doxorubicin is being used to treat certain forms of cancer, while liposomal amphotericin B treats fungal infections often associated with aggressive anticancer treatments.
  • Recently, a nanoparticulate formulation of the well-known anticancer compound taxol was submitted to the FDA as a new treatment for advanced-stage breast cancer.

Other clinical applications of nanotechnology have focused on identifying cancer in its earliest stages, visualizing development of the disease, delivering improved therapy to increase the effectiveness and reduce side effects of drugs, and capturing early signals of drug efficacy.

For additional information about the NCI Alliance for Nanotechnology in Cancer, please go to: nano.cancer.gov.

To view an archived copy of the video Web cast of the NCI press briefing on the Nanotechnology Cancer Alliance, please go to: videocast.nih.gov/PastEvents.asp.

For more information about cancer, please visit the NCI Web site at www.cancer.gov or call NCI's Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).

Contact:

NCI Press Office
301-496-6641

Copyright © National Institutes of Health

If you have a comment, please us.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

National Cancer Institute

Related News Press

Possible Futures

A novel method for identifying the body’s ‘noisiest’ networks November 19th, 2014

Researchers discern the shapes of high-order Brownian motions November 17th, 2014

VDMA Electronics Production Equipment: Growth track for 2014 and 2015 confirmed: Business climate survey shows robust industry sector November 14th, 2014

Open Materials Development Will Be Key for HP's Success in 3D Printing: HP can make a big splash in 3D printing, but it needs to shore up technology claims and avoid the temptation of the razor/razor blade business model in order to flourish November 11th, 2014

Investments/IPO's/Splits

Nanometrics Announces Upcoming Investor Events November 19th, 2014

Eight19 secures £1m funding: Investment to develop production technology, and expand commercial activities for organic photovoltaics November 19th, 2014

Arrowhead to Present at Upcoming Conferences November 15th, 2014

Harris & Harris Group Reports Financial Statements as of September 30, 2014 November 11th, 2014

Nanomedicine

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research reveals how our bodies keep unwelcome visitors out of cell nuclei November 24th, 2014

ASU, IBM move ultrafast, low-cost DNA sequencing technology a step closer to reality November 24th, 2014

An Inside Job: UC-Designed Nanoparticles Infiltrate, Kill Cancer Cells From Within November 24th, 2014

Announcements

Renishaw receives Queen's Award for spectroscopy developments November 25th, 2014

JPK reports on the use of AFM and the CellHesion module to study plant cells at the University of Queensland November 25th, 2014

Vegetable oil ingredient key to destroying gastric disease bacteria: In mice, therapeutic nanoparticles dampen H. pylori bacteria and inflammation that lead to ulcers and gastric cancer November 25th, 2014

Research yields material made of single-atom layers that snap together like Legos November 25th, 2014

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More












ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2014 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE